ArticleFrontiers in psychiatry2026
Validation of the Chinese version of Morningness-Eveningness Questionnaire for screening delayed sleep-wake phase disorder with bipolar disorder among Han Chinese population.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Delayed sleep-wake phase disorder (DSWPD) is commonly seen in bipolar disorder (BD). However, valid screening tools for DSWPD have not been available, especially in China. Therefore, this study aimed to explore the validation of the Morningness-Eveningness Questionnaire (MEQ) for screening DSWPD with BD among Han Chinese population. Methods: Results: The internal consistency, split-half, and retest reliabilities of the MEQ were 0.758, 0.719, and 0.661, respectively. Three factors were obtained for the MEQ scale based on Exploratory factor analysis, with a cumulative factor loading of 37.384%. BD patients with DSWPD had significantly lower MEQ scores (36.85 ± 6.40) compared to BD patients without DSWPD (47.44 ± 7.39) and healthy controls (47.96 ± 7.28) (both p<0.001). The area under the ROC curve (AUC) was 0.867. The Youden index was the highest when a MEQ score of 43 was used as the cut-off point, with a sensitivity of 0.83 and a specificity of 0.75. Conclusion: The Chinese version of MEQ is a valid screening tool for DSWPD among bipolar disorder patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.